OPROMA
comp 80336 München - Deutschland
Biologielaborant/in Arbeit Vollzeit ab 01.01.2027
Infos zum Berufsbild: Aufgaben, Gehalt & Karriere
Anzeige

Beschreibung

Scope of duties · Develop and optimize CAR constructs and support their transfer into a scalable retroviral vector system· Generate and characterize CAR T cells and assess their functionality in vitro using AML cell lines and primary patient samples· Investigate CAR T-cell cytotoxicity, activation, differentiation, and proliferation.· Evaluate potential off-target effects and hematopoietic toxicity using humanized mouse models and healthy human tissue explant models· Analyze experimental data, document results, and contribute to scientific publications and preclinical safety evaluation· Collaborate with interdisciplinary research teams within the CARAMeL consortium Our requirements · PhD, MD, PharmD, DVM, or an equivalent doctoral degree in immunology, molecular or cell biology, biochemistry, biomedical sciences, or a related field · Strong experimental research experience and a good publication record· Solid knowledge of immunology and cell biology, with practical experience in cell culture and functional assays· Experience in one or more of the following areas is highly desirable: CAR T-cell engineering, viral vector technology, flow cytometry, or preclinical in vivo models· Strong analytical skills and an independent, structured approach to research· High motivation, initiative, and the ability to work collaboratively in an international research environment· Excellent written and spoken English Our offer · Contract duration: 2 years fixed-term· The Institute of Clinical Pharmacology at LMU University Hospital Munich offers an interdisciplinary research environment at the interface of experimental immunology, innovative cell therapies, and translational medicine · The research group of Prof. Dr. Sebastian Kobold focuses on developing novel cancer immunotherapies, particularly cellular therapies and antibody-based approaches· This position is part of the CARAMeL consortium, funded by the German Cancer Consortium (DKTK). The project aims to advance an innovative CAR T-cell therapy for patients with relapsed or refractory acute myeloid leukemia (AML). A key objective is to improve therapeutic efficacy while minimizing damage to healthy hematopoietic stem and progenitor cells· The successful candidate will contribute to translating the CAR technology into a scalable retroviral vector system and investigating the functionality and preclinical safety of the resulting CAR T cells. The work will be conducted in close collaboration with national and international research partners
Vollständige Beschreibung anzeigen

Scope of duties

· Develop and optimize CAR constructs and support their transfer into a scalable retroviral vector system
· Generate and characterize CAR T cells and assess their functionality in vitro using AML cell lines and primary patient samples
· Investigate CAR T-cell cytotoxicity, activation, differentiation, and proliferation.
· Evaluate potential off-target effects and hematopoietic toxicity using humanized mouse models and healthy human tissue explant models
· Analyze experimental data, document results, and contribute to scientific publications and preclinical safety evaluation
· Collaborate with interdisciplinary research teams within the CARAMeL consortium

Our requirements

· PhD, MD, PharmD, DVM, or an equivalent doctoral degree in immunology, molecular or cell biology, biochemistry, biomedical sciences, or a related field

· Strong experimental research experience and a good publication record
· Solid knowledge of immunology and cell biology, with practical experience in cell culture and functional assays
· Experience in one or more of the following areas is highly desirable: CAR T-cell engineering, viral vector technology, flow cytometry, or preclinical in vivo models
· Strong analytical skills and an independent, structured approach to research
· High motivation, initiative, and the ability to work collaboratively in an international research environment
· Excellent written and spoken English

Our offer

· Contract duration: 2 years fixed-term
· The Institute of Clinical Pharmacology at LMU University Hospital Munich offers an interdisciplinary research environment at the interface of experimental immunology, innovative cell therapies, and translational medicine

· The research group of Prof. Dr. Sebastian Kobold focuses on developing novel cancer immunotherapies, particularly cellular therapies and antibody-based approaches
· This position is part of the CARAMeL consortium, funded by the German Cancer Consortium (DKTK). The project aims to advance an innovative CAR T-cell therapy for patients with relapsed or refractory acute myeloid leukemia (AML). A key objective is to improve therapeutic efficacy while minimizing damage to healthy hematopoietic stem and progenitor cells
· The successful candidate will contribute to translating the CAR technology into a scalable retroviral vector system and investigating the functionality and preclinical safety of the resulting CAR T cells. The work will be conducted in close collaboration with national and international research partners

Arbeitgeber: Klinikum der Universität München

Stellenanzeige bei der Bundesagentur für Arbeit ansehen
Anzeige
Bewerben

Weiter zur externen Bewerbung

Du verlässt das OPROMA-Portal. Den Bewerbungsweg findest du auf der Zielseite.

Stellenquelle
Bundesagentur für Arbeit
Zielwebsite
www.arbeitsagentur.de

Die Zielseite öffnet sich in einem neuen Tab. Dort gelten die Datenschutzbestimmungen des jeweiligen Anbieters.

Ref-Nr.: 14662877
Aktualisiert: 19.11.2026
Quelle: Bundesagentur für Arbeit
weitere Infos

Angebote merken und später wiederfinden

Mit deinem kostenlosen OPROMA-Profil.

Kostenloses Profil erstellen